LONDON — A single infusion of the anti-CD20 antibody rituximab (Rituxan, Genentech, Inc) can delay the onset of rheumatoid arthritis for up to a year in individuals at high risk of developing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results